Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Hypertensive Disorders of Pregnancy
Author(s): Ariana Traub , Apoorva Sharma , Maria Carolina Gongora Added: 1 year ago

Prevention & Chronic Conditions
Assessing Pregnancy Risk in Patients with Congenital Heart Disease
Author(s): Ajitha Kulasekaran , Lorna Swan Added: 2 years ago

Demographic

Inherited and Congenital Cardiac Conditions
New ESC Guidelines for the Management of Hypertension
Author(s): Rhian Touyz Added: 8 months ago
ESC Congress 2024 — Dr Rhian Touyz (McGill University Health Center, CA) joins us to discuss key highlights from the ESC 2024 guidelines for the management of elevated blood pressure and hypertension.The new guidelines introduce a new systolic blood pressure treatment target range of 120-129 mmHg, placing emphasis on an intensive target treatment as the first step in patient management - only… View more

Prevention & Chronic Conditions
AHA 23 Late-Breaker Discussion: Hypertension Treatment in Nigeria Program
Author(s): Harriette Van Spall , Dike Bevis Ojji Added: 1 year ago
AHA 2023 — Investigator Dr Dike Bevis Ojji (University of Abuja, NG) talks with Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) about the Hypertension Treatment in Nigeria Program (NCT04158154).The aim of this study (Washington University School of Medicine) and employing an interrupted time series design, is to assess the implementation and evaluation of a culturally- and… View more

Prevention & Chronic Conditions
ACC 25 Late-Breaking Discussion: The ADVANCE-HTN Trial
Author(s): Harriette Van Spall , Luke Laffin Added: 1 month ago
ACC 25 - ADVANCE-HTN shows lorundrostat, an aldosterone synthase inhibitor, effectively lowered 24-hour blood pressure in patients with uncontrolled and true resistant hypertension.Late-breaker discussion host, Dr Harriette Van Spall (McMaster University, Hamilton, CA) is joined by Dr Luke Laffin (Cleveland Clinic, Cleveland, OH, US) to discuss the key findings from the ADVANCE-HTN trial… View more

Prevention & Chronic Conditions
Research Area(s) / Expertise: Job title: T32 Postdoctoral Researcher, Clinical Instructor of Medicine, Division of Cardiology
Agnes Koczo is a post-doctoral researcher and cardiologist at the University of Pittsburgh Medical Center. She completed both her residency and fellowship training with chief designation at the University of Pittsburgh and with special focus on women's health. Her fellowship and post-doctoral research focuses on a number of cardiovascular conditions that exclusively or disproportionately impact… View more
Left Atrial Myxoma
Author(s): Preet Shaikh , Mario Rodriguez Rivera , Michael A Beal , et al Added: 6 months ago

Heart Failure

Prevention & Chronic Conditions
AHA 23: KABUKI: DOAC in Pts with CTEPH
Author(s): Kazuya Hosokawa , Abe Kotaro Added: 1 year ago
AHA 2023 — Dr Kazuya Hosokawa and Dr Abe Kotaro (Kyushu University Hospital, JP) join us to share the findings of the KABUKI trial (NCT04730037). The aim of KABUKI (Daiichi Sankyo) is to assess whether edoxaban, a direct factor Xa inhibitor, is noninferior to warfarin in preventing worsening of chronic thromboembolic pulmonary hypertension (CTEPH).This investigator-initiated, multicenter, phase 3… View more

Prevention & Chronic Conditions
ACC.24: Zilebesiran in Patients With Hypertension: KARDIA-2
Author(s): Akshay S Desai Added: 1 year ago
ACC.24 — We are joined onsite by investigator, Dr Akshay Desai (Brigham and Women's Hospital, US) to discuss the findings from the KARDIA-2 randomized clinical trial (NCT05103332).KARDIA-2 is a double-blind, placebo-controlled multicenter study aiming to evaluate the effects of zilebesiran, an RNA interference agent, on the systolic and diastolic blood pressure of hypertensive patients not… View more

Prevention & Chronic Conditions
CardioNerds @AHA23: KARDIA-1: ALN-AGT01 in Patients With Mild-to Moderate Hypertension
Author(s): George L Bakris , Sukriti Banthiya Added: 1 year ago
AHA 2023 — Investigator, Dr George Bakris (UChicago Medicine, US) is interviewed by Dr Sukriti Banthiya, CardioNerds Ambassador on the new findings of KARDIA-1 trial (NCT04936035).This randomized, double-blind, placebo-controlled, dose-ranging multicenter study (Alnylam Pharmaceuticals) aimed to evaluate the effect of ALN-AGT01 (zilbesiran) on systolic and diastolic blood pressure in patients… View more

Prevention & Chronic Conditions